ClinicalTrials.gov
public full text
Public Domain
Blood-Brain Barrier Penetration of Therapeutic Agents in Human
This is a phase 1, open-label, non-randomized, exploratory, repeated dose PK study performed at a single centre. Up to 6 evaluable subjects are planned. The subjects will receive p.o. doses of ODM-104 for 5-7 days. Single dose of paracetamol will be administered p.o. together with ODM-104 for purposes of comparison.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders#904342
- Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants#1114028
- Safety and PK/PD of RTA 1701 in Healthy Adults#857808
- Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)#1085890
- A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers#803409
Record · ID 861341
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive